Posts tagged MDVN


Company Update (NASDAQ:MDVN): Medivation Inc Highlights New Data From Differentiated Oncology Portfolio at ESMO 2016

Medivation Inc (NASDAQ:MDVN) announced that new data from Company-sponsored and investigator-initiated clinical trials will be presented …

Brean Capital Downgrades Medivation Inc (MDVN) in Wake of Pfizer Merger Agreement

Pfizer will acquire Medivation for $81.50 per share in cash- an offer unlikely to be bested, says Brean Capital

Analysts Give Their Two Cents on Medivation Inc (MDVN) and Pfizer Inc. (PFE) Following Acquisition News

Today’s biggest news is coming from Pfizer Inc. (NYSE:PFE), which announced its offer to acquire …

Company Update (NASDAQ:MDVN): Medivation Inc to Be Acquired by Pfizer for $81.50 a Share in Cash

Medivation, Inc. (NASDAQ:MDVN) and Pfizer Inc. (NYSE:PFE) announced that they have entered into a definitive merger …

Canaccord Shines Light on Medivation Inc’s (MDVN) 2Q:16 Results

In a research report published Wednesday, Canaccord analyst John Newman reiterated a Buy rating on …

Company Update (NASDAQ:MDVN): Medivation Inc Reports Second Quarter 2016 Financial Results

Medivation Inc (NASDAQ:MDVN) reported its financial results for the quarter ended June 30, 2016 and reaffirmed …

Leerink Partners Analyst Believes Medivation Inc’s (MDVN) New Pipeline Drug May Lead to Another Round of Takeout Bids

Analyst Geoff Porges of Leerink Partners discussed Medivation Inc’s (NASDAQ:MDVN) pipeline drug, talazoparib, after listening into a …

Earnings Preview: Jefferies Weighs In on Gilead Sciences, Inc. (GILD), Medivation Inc (MDVN) and Amarin Corporation plc (ADR) (AMRN)

With earning season for Biotech companies approaching, Jefferies’ analysts detailed their thoughts on several mid …

Stock Update (NASDAQ:MDVN): Glass Lewis Recommends Medivation Inc’s Stockholders Support the Company’s Current Board

Medivation Inc (NASDAQ:MDVN) announced that independent proxy advisory firm Glass, Lewis & Co., LLC (“Glass Lewis”) …

Company Update (NASDAQ:MDVN): Medivation Inc’s Pidilizumab Shows Potential Clinical Benefit and Safety in Children With Diffuse Intrinsic Pontine Glioma

Medivation Inc (NASDAQ:MDVN) announced results from a Phase I/II study of pidilizumab, an investigational antibody with …

Show More